Literature DB >> 10225726

Ability to remove immunoglobulins and antiganglioside antibodies by double filtration plasmapheresis in Guillain-Barré syndrome: is it equivalent to plasma exchange?

Y Tagawa1, N Yuki, K Hirata.   

Abstract

The value of plasma exchange (PE) in Guillain-Barré syndrome (GBS) is well established. In Japan, patients with GBS and related diseases often receive double filtration plasmapheresis (DFPP) as well as PE. No comparative trials between PE and DFPP, however, have been conducted. We compared their abilities to remove immunoglobulins and antiganglioside antibodies to find out whether DFPP is equivalent to PE. The ability to remove immunoglobulins and antiganglioside antibodies was compared between PE and DFPP using plasma samples from 41 patients with GBS and related diseases before and after each treatment session. The ability of DFPP to remove both IgGs and antiganglioside IgG antibodies were significantly inferior to those of PE. There is a less theoretical basis for selecting DFPP as the first choice of plasmapheresis for GBS and related disorders.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 10225726     DOI: 10.1111/j.1744-9987.1997.tb00050.x

Source DB:  PubMed          Journal:  Ther Apher        ISSN: 1091-6660


  3 in total

1.  Guillain-Barré Syndrome.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-11       Impact factor: 3.972

2.  Lower In-Hospital Mortality with Plasma Exchange than Plasmapheresis in a Subgroup Analysis of 374 Lupus Patients.

Authors:  Yu-Jih Su; Wen-Chan Chiu; Chung-Yuan Hsu; Jin-Bor Chen; Hwee-Yeong Ng
Journal:  Biomed Res Int       Date:  2018-05-02       Impact factor: 3.411

3.  Effect of Double Filtration Plasmapheresis on Various Plasma Components and Patient Safety: A Prospective Observational Cohort Study.

Authors:  K Jagdish; S Jacob; S Varughese; V G David; A Mohapatra; A Valson; K Tulsidas; T Veerasami; S Alexander
Journal:  Indian J Nephrol       Date:  2017 Sep-Oct
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.